TABLE 4.

GRADE profile of statins for HDRS, rate of response, and remission rate.

Quality assessment							No. of patients		Effect	Quality
No. of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Statins	Control	MD/RR (95% CI)
HDRS (follow-up 6–12 weeks; better indicated by lower values)
7	Randomized trials	No serious risk of bias	Serious1	No serious indirectness	No serious imprecision	None	223	‘225	–2.79 (-3.83, –1.76)4	MODER-ATE
Rate of response (follow-up 6–12 weeks; better indicated by higher values)
4	Randomized trials	No serious risk of bias	No serious2	No serious indirectness	No serious imprecision	None	152	148	1.26 (0.98, 1.62)	MODER-ATE
Remission rate (follow-up 6–12 weeks; better indicated by lower values)
4	Randomized trials	No serious risk of bias	No serious3	No serious indirectness	No serious imprecision	None	155	158	1.33 (0.89, 1.99)	LOW

¹The test for heterogeneity is not significant, and the I² is high, 0.0%. ²The test for heterogeneity is not significant, and the I² is low, I² = 0.0% ³The test for heterogeneity is not significant, and the I² is low, I² = 20.7% ⁴Effect is the mean difference and 95% CI. HDRS, Hamilton depression rating scale; MD, mean difference; RR, relative risk; CI, confidence interval.